AKT1 polymorphisms and survival of early stage non‐small cell lung cancer
暂无分享,去创建一个
Dong Sun Kim | Jae Hee Lee | H. Jeon | S. Kam | T. Jung | E. Lee | Shin‐Yup Lee | M. Kim | Shin Yup Lee | Chang-Ho Kim | W. Lee | S. Cha | Hyo‐Gyoung Kang | Ji Young Park | Jae-Yong Park | Hyo-Gyoung Kang
[1] H. Jeon,et al. Polymorphisms in Apoptosis-Related Genes and Survival of Patients with Early-Stage Non-Small-Cell Lung Cancer , 2010, Annals of Surgical Oncology.
[2] Dong Sun Kim,et al. Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] L. Tanoue,et al. The new lung cancer staging system. , 2009, Chest.
[4] J. Lieberman,et al. Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia , 2008, Schizophrenia Research.
[5] Gaetano Rocco,et al. Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung , 2008, Cell cycle.
[6] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[7] Xihong Lin,et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Sheng Li,et al. Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. , 2007, The Journal of clinical psychiatry.
[9] D. Neuberg,et al. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. Miller,et al. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. , 2007, Oncology reports.
[11] Zhifu Sun,et al. Gene Expression Profiling on Lung Cancer Outcome Prediction: Present Clinical Value and Future Premise , 2006, Cancer Epidemiology Biomarkers & Prevention.
[12] T. Asada,et al. Failure to support a genetic contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia , 2006, Journal of neurochemistry.
[13] J. Park,et al. Caspase 9 promoter polymorphisms and risk of primary lung cancer. , 2006, Human molecular genetics.
[14] A. Levine,et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[15] W. Maier,et al. Further Evidence for Association of Variants in the AKT1 Gene with Schizophrenia in a Sample of European Sib-Pair Families , 2005, Biological Psychiatry.
[16] Y. Miller. Pathogenesis of lung cancer: 100 year report. , 2005, American journal of respiratory cell and molecular biology.
[17] W. Tan,et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer , 2005, Journal of Medical Genetics.
[18] Sunil Singhal,et al. Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non–Small Cell Lung Cancer: A Review , 2005, Clinical Cancer Research.
[19] K. O'Byrne,et al. Phospho-Akt Expression Is Associated with a Favorable Outcome in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[20] M. Daly,et al. Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..
[21] B. Ponder,et al. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. , 2004, Journal of the National Cancer Institute.
[22] M. Ikeda,et al. Association of AKT1 with schizophrenia confirmed in a Japanese population , 2004, Biological Psychiatry.
[23] D. Neuberg,et al. Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy , 2004, Clinical Cancer Research.
[24] A. Loktionov. Common gene polymorphisms, cancer progression and prognosis. , 2004, Cancer letters.
[25] M. Karayiorgou,et al. Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia , 2004, Nature Genetics.
[26] Bengt Bergman,et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.
[27] L. Cantley,et al. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.
[28] Alfonso Bellacosa,et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. , 2003, Cancer research.
[29] C. Sawyers,et al. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.
[30] S. Gabriel,et al. The Structure of Haplotype Blocks in the Human Genome , 2002, Science.
[31] P. Dennis,et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.
[32] P. Donnelly,et al. A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.
[33] S. R. Datta,et al. Cellular survival: a play in three Akts. , 1999, Genes & development.
[34] R. Busse,et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation , 1999, Nature.
[35] J. Minna,et al. Molecular genetics of lung cancer. , 1988, Annual review of medicine.
[36] G. Viglietto,et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. , 2008, Cell cycle.
[37] J. Testa,et al. Activation of AKT kinases in cancer: implications for therapeutic targeting. , 2005, Advances in cancer research.
[38] E. Lander,et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. , 2001, Proceedings of the National Academy of Sciences of the United States of America.